Alkermes plc (ALKS)
NASDAQ:ALKS
Want to see ALKS full AI Analyst Report?
Earnings Data
Report Date
Jul 29, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.01Last Year’s EPS
0.67Same Quarter Last Year
Strong Buy
Based on 14 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call communicated strong commercial momentum, sizable year-over-year revenue growth (+38% for proprietary products), an encouraging early LUMRYZ launch with meaningful sales and patient growth, a material adjusted EBITDA beat, and clear pipeline progress with Phase III initiation and multiple new programs underway. Offsetting factors include a GAAP net loss and negative GAAP EBITDA in the quarter, elevated R&D and SG&A as programs scale and integration costs are realized, increased leverage and near-term margin pressure from inventory step-up and widening gross-to-net. On balance, the positives (revenue growth, LUMRYZ contribution, adjusted EBITDA beat, improved purchase price accounting and an expanding orexin pipeline) meaningfully outweigh the near-term financial and execution headwinds.Company Guidance
Strong Topline Growth
Net sales from proprietary products increased 38% year-over-year to $338.1 million in Q1 2026, contributing to total revenues of $392.9 million for the quarter.
Robust Performance Across Key Brands
VIVITROL Q1 net sales of $112.4M (2026 guidance $460M–$480M); ARISTADA Q1 net sales of $93.8M (2026 guidance $365M–$385M); LYBALVI Q1 net sales of $92.4M, up 32% YoY with TRX growth of 21% YoY and 2026 guidance $380M–$400M.
Successful Acquisition and LUMRYZ Launch Momentum
Closed Avadel acquisition mid-February. LUMRYZ recorded approximately $39.5M of net sales in the 6 weeks post-close and ~ $72M for the full quarter reported; exited the quarter with ~3,600 patients on therapy (brand patient count growth ~28% YoY). Full-year LUMRYZ net sales guidance $350M–$370M (Alkermes share $315M–$335M).
Adjusted EBITDA Beat and Improved Near-Term Outlook
Generated adjusted EBITDA of $80.3M in Q1, well above prior Q1 guidance of $30M–$50M; Q2 adjusted EBITDA expected $100M–$120M. Full-year EBITDA outlook improved to positive $105M–$135M after purchase price accounting refinements.
Purchase Price Accounting Refinements Reduced Expected Charges
Inventory step-up expense for LUMRYZ now expected ~$105M in 2026 (vs prior ~$150M), lowering expected 2026 COGS to $320M–$340M (from prior $365M–$385M). Full-year amortization of intangibles revised down to $75M–$85M (from $95M–$105M).
Progressing a Broad Orexin Pipeline
Alixorexton Brilliance Phase III is open for enrollment in NT1 and NT2; Vibrance-2 (NT2) data to be presented in June; Vibrance-3 (IH) Phase II on track to complete in Q4. New molecules ALKS 7290 (ADHD) and ALKS 4510 (fatigue in MS/Parkinson’s) advancing—Phase Ib ADHD data expected Q4 2026 and Phase II (~300 pts) planned for 2026/2027.
Balance Sheet Actions and Share Repurchase
Ended Q1 with ~$538M cash and investments after deploying ~$775M cash toward Avadel acquisition and entering $1.525B term loans due 2031; repurchased ~1M shares for $28M with $172M remaining authorization.
ALKS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ALKS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 05, 2026 | $34.17 | $36.25 | +6.09% |
Feb 25, 2026 | $33.39 | $31.04 | -7.04% |
Oct 28, 2025 | $29.72 | $31.00 | +4.31% |
Jul 29, 2025 | $26.15 | $27.00 | +3.25% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Alkermes plc (ALKS) report earnings?
Alkermes plc (ALKS) is schdueled to report earning on Jul 29, 2026, Before Open (Confirmed).
What is Alkermes plc (ALKS) earnings time?
Alkermes plc (ALKS) earnings time is at Jul 29, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ALKS EPS forecast?
ALKS EPS forecast for the fiscal quarter 2026 (Q2) is -0.01.